Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Beneish M-Score: -2.62 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603392 Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHSE:603392
53 GF Score
Price ¥29.45
GF Value ¥42.07
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Beijing Wantai Biological Pharmacy Enterprise Co Beneish M-Score?

Beijing Wantai Biological Pharmacy Enterprise Co SHSE:603392 +0.86% 53 Beneish M-Score is -2.62 as of Jul. 29, 2026. GuruFocus rates SHSE:603392 with a GF Score™ of 53/100 and a GF Value™ of ¥42.07 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 824 Biotechnology companies, Beijing Wantai Biological Pharmacy Enterprise Co ranks better than 61.17% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.62 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Beijing Wantai Biological Pharmacy Enterprise Co's Beneish M-Score or its related term are showing as below:

SHSE:603392' s Beneish M-Score Range Over the Past 10 Years
Min: -2.86   Med: -1.8   Max: -0.41
Current: -2.62

During the past 13 years, the highest Beneish M-Score of Beijing Wantai Biological Pharmacy Enterprise Co was -0.41. The lowest was -2.86. And the median was -1.80.


Beijing Wantai Biological Pharmacy Enterprise Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Beijing Wantai Biological Pharmacy Enterprise Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Wantai Biological Pharmacy Enterprise Co Beneish M-Score Chart

Beijing Wantai Biological Pharmacy Enterprise Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.15 -1.42 -2.17 -2.13 -2.59

Beijing Wantai Biological Pharmacy Enterprise Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.49 -2.67 -2.86 -2.59 -2.62

SHSE:603392 vs VRTX, REGN, RVMD: Beneish M-Score Comparison

For the Biotechnology subindustry, Beijing Wantai Biological Pharmacy Enterprise Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Wantai Biological Pharmacy Enterprise Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Wantai Biological Pharmacy Enterprise Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Beijing Wantai Biological Pharmacy Enterprise Co's Beneish M-Score falls into.


SHSE:603392
53GF Score
Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHSE:603392
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Wantai Biological Pharmacy Enterprise Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Beijing Wantai Biological Pharmacy Enterprise Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7723+0.528 * 1.2626+0.404 * 1.1352+0.892 * 1.0254+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.4062+4.679 * -0.024138-0.327 * 0.8901
=-2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥1,545 Mil.
Revenue was 523.345 + 320.598 + 654.808 + 442.937 = ¥1,942 Mil.
Gross Profit was 365.597 + 94.285 + 293.746 + 242.487 = ¥996 Mil.
Total Current Assets was ¥6,731 Mil.
Total Assets was ¥13,761 Mil.
Property, Plant and Equipment(Net PPE) was ¥3,493 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥255 Mil.
Total Current Liabilities was ¥1,598 Mil.
Long-Term Debt & Capital Lease Obligation was ¥106 Mil.
Net Income was -42.984 + -224.846 + -29.384 + -91.261 = ¥-388 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -232.044 + 82.469 + 73.838 + 19.42 = ¥-56 Mil.
Total Receivables was ¥1,952 Mil.
Revenue was 400.625 + 297.292 + 582.066 + 613.532 = ¥1,894 Mil.
Gross Profit was 266.622 + 162.975 + 374.182 + 422.754 = ¥1,227 Mil.
Total Current Assets was ¥7,629 Mil.
Total Assets was ¥14,470 Mil.
Property, Plant and Equipment(Net PPE) was ¥3,564 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥177 Mil.
Total Current Liabilities was ¥1,844 Mil.
Long-Term Debt & Capital Lease Obligation was ¥168 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1545.469 / 1941.688) / (1951.535 / 1893.515)
=0.795941 / 1.030641
=0.7723

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1226.533 / 1893.515) / (996.115 / 1941.688)
=0.647755 / 0.513015
=1.2626

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6730.936 + 3492.619) / 13760.997) / (1 - (7629.26 + 3563.822) / 14469.838)
=0.257063 / 0.226454
=1.1352

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1941.688 / 1893.515
=1.0254

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 3563.822)) / (0 / (0 + 3492.619))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(254.81 / 1941.688) / (176.702 / 1893.515)
=0.131231 / 0.09332
=1.4062

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((105.6 + 1598.065) / 13760.997) / ((168.146 + 1844.367) / 14469.838)
=0.123804 / 0.139083
=0.8901

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-388.475 - 0 - -56.317) / 13760.997
=-0.024138

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Beijing Wantai Biological Pharmacy Enterprise Co has a M-score of -2.62 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.62 mean?
Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) has a Beneish M-Score of -2.62 as of Jul. 29, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. According to the industry distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #320 out of 824 companies in the Biotechnology industry, placing it in the top 38.8%.
Is Beijing Wantai Biological Pharmacy Enterprise Co's Beneish M-Score too high?
Beijing Wantai Biological Pharmacy Enterprise Co's current Beneish M-Score is -2.62. Based on the distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #320 out of 824 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beijing Wantai Biological Pharmacy Enterprise Co has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beijing Wantai Biological Pharmacy Enterprise Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #320 out of 824 companies for Beneish M-Score. This puts Beijing Wantai Biological Pharmacy Enterprise Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. Beijing Wantai Biological Pharmacy Enterprise Co's current Beneish M-Score is -2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Wantai Biological Pharmacy Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) is currently considered Possible Value Trap. The stock's GF Value™ is ¥42.07, compared to a current price of ¥29.45 — trading 30% below its estimated fair value. The current Beneish M-Score is -2.62. Beijing Wantai Biological Pharmacy Enterprise Co's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392), the current Beneish M-Score is -2.62 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co stock appears to be undervalued. The current stock price of ¥29.45 is trading 30% below its estimated GF Value™ of ¥42.07. GuruFocus considers Beijing Wantai Biological Pharmacy Enterprise Co to be Possible Value Trap.

Key valuation signals for SHSE:603392:

  • Beneish M-Score: -2.62
  • GF Value™: ¥42.07 vs. price of ¥29.45 (30% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603392 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beijing Wantai Biological Pharmacy Enterprise Co Business Description

Address No. 31, Science Park Road, Changping District, Beijing, CHN, 102206
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
53GF Score

Get the complete analysis for SHSE:603392

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥29.45
Price
¥42.07
GF Value